CA-ESRI
30.11.2021 14:03:00 CET | Business Wire | Press release
A new app that can manage conservation plans and verify corporate environmental promises with clear imagery from the sky is being powered in partnership with Esri and its ArcGIS Image for ArcGIS Online. The Ranger app from Skytec, a Chattanooga, Tennessee-based geospatial and remote sensing firm, uses aerial drones and satellite imagery to remotely monitor a subscriber's property from above.
Ranger provides notifications when changes emerge, without the costly expense and time spent for on-site monitoring. Observable changes to the land could include encroachment by others; deforestation; impending pest infestations; and other environmental concerns including natural and unnatural disasters such as floods, fires, and spills.
"ArcGIS Image for ArcGIS Online has given us more time to focus on what we do best—analysis—rather than having to stand up the infrastructure operating behind the scenes. With Esri, those secure back-end systems are built in," said Skytec Chief Technology Officer Andrew Carroll.
The technology from Redlands, California-based Esri, the global leader in location intelligence, processes and securely stores the imagery powering Skytec's Ranger app in the cloud.
"Being able to understand and accurately measure success is half the battle in conservation, and this app allows users to know the precise impact of their efforts," said Jack Dangermond, Esri founder and president. "Skytec created the kind of sustainable solution our world needs to solve urgent climate concerns, and we're pleased to partner in providing the tools to help the firm grow."
Through Ranger, customers can choose how frequently they receive timed reports showing activity and highlighting changes on the areas they want monitored. If customers want more information about a change event, they can order higher-resolution satellite or drone imagery captured with lidar or send their own staff to observe in person. Those choices are then coordinated through Esri's ArcGIS Survey123 application.
Ranger is already monitoring more than 100,000 acres across the country with help from ArcGIS Image for ArcGIS Online. Among its clients are the Palmer Land Conservancy and the Hudson Highlands Land Trust.
Skytec CEO Bill Rogers and Carroll started the company as commercial drone operations began to take off, by monitoring small sites with unmanned aerial vehicles before expanding to include piloted flight observations. Now, with satellite imagery from Planet, Skytec wants Ranger to be a global solution to climate change by providing macro views of land showing if conservation strategies are working.
"We're anticipating clients' needs for seamless monitoring at any level of any location around the globe," Rogers said. "This service is beneficial for clients in a variety of industries, from natural resource management to environmental mitigation firms and utilities."
The application also has the potential to prove an entity has kept its environmental promises.
"There's an opportunity to begin to come in and fill the data science needs that are behind corporate sustainability initiatives," Carroll said. Monitoring can show where mitigation measures have been made, where growth has occurred, and what, if any, recovery has been achieved. It can also monitor for carbon offsets and ecological ecosystem banking.
"Everyone's talking a great talk, but where's the data behind it," Carroll said of what Ranger provides.
The Ranger application, built with Esri's ArcGIS Web AppBuilder, is optimized for desktop and tablet use. The partnership with Esri also gives Skytec and its Ranger customers access to the mapping leader's extensive library of online data, including its ArcGIS Living Atlas of the World, and a seamless experience for existing Esri users.
To learn how Esri can help businesses more easily access, process, and manage imagery in the cloud, visit go.esri.com/arcgisimage .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom